logo-loader
viewRedx Pharma PLC

Redx Pharma chief "encouraged" by latest data on fibrosis drug candidate

Redx Pharma Plc’s (LON:REDX) chief executive Lisa Anson tells Proactive London how “encouraged” she and the company is about the latest pre-clinical data from a fibrosis drug set to enter human trials next year.News here too on what this means for the company and indeed fibrosis sufferers themselves.The lab tests showed the Redx drug was able to suppress collagen deposition and pathways associated with fibrosis, meaning it could have an impact on established forms of the disease.
Its profile suggests the putative treatment is suitable to be taken by mouth, rather than injected directly into the blood system.
Three independent studies assessed the potential efficacy of the company’s lead ROCK2 compound in animal models of lung, kidney and liver fibrosis.

Quick facts: Redx Pharma PLC

Price: 14.25 GBX

AIM:REDX
Market: AIM
Market Cap: £27.08 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Redx Pharma PLC named herein, including the promotion by the Company of Redx Pharma PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Morning Report: FTSE 100 rallies as Italians ban short selling

Headlines from the Proactive UK newsroom. The FTSE 100 rallied this morning even though Asian markets suffered more pain overnight.  London’s blue chip index opened around 157 points higher at 5,395 after giving up 639 points yesterday. Italy has introduced a temporary ban on...

2 weeks, 3 days ago

2 min read